World Journal of Surgical Oncology (Jul 2011)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib

  • M'rabti Hind,
  • Ahellal Youness,
  • Tazi Mohamed,
  • Essadi Ismail,
  • Tazi El,
  • Errihani Hassan

DOI
https://doi.org/10.1186/1477-7819-9-73
Journal volume & issue
Vol. 9, no. 1
p. 73

Abstract

Read online

Abstract Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.

Keywords